Sage Therapeutics, Inc.
SAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $329,959 | $1,296,656 | $2,261,934 | $2,495,832 |
| - Cash | $81,021 | $70,992 | $162,700 | $294,233 |
| + Debt | $11,836 | $5,165 | $12,134 | $18,432 |
| Enterprise Value | $260,774 | $1,230,829 | $2,111,368 | $2,220,031 |
| Revenue | $41,243 | $86,455 | $7,686 | $6,308 |
| % Growth | -52.3% | 1,024.8% | 21.8% | – |
| Gross Profit | $31,799 | $84,296 | $6,873 | $5,755 |
| % Margin | 77.1% | 97.5% | 89.4% | 91.2% |
| EBITDA | -$409,485 | -$545,070 | -$545,867 | -$456,727 |
| % Margin | -992.9% | -630.5% | -7,102.1% | -7,240.4% |
| Net Income | -$400,666 | -$541,489 | -$503,267 | -$450,827 |
| % Margin | -971.5% | -626.3% | -6,547.8% | -7,146.9% |
| EPS Diluted | -6.59 | -9.05 | -8.49 | -7.68 |
| % Growth | 27.2% | -6.6% | -10.5% | – |
| Operating Cash Flow | -$267,194 | -$540,585 | -$460,036 | -$378,182 |
| Capital Expenditures | $0 | -$553 | -$937 | -$372 |
| Free Cash Flow | -$267,194 | -$541,138 | -$460,973 | -$378,554 |